New AstraZeneca COVID-19 Vaccine data further support its use as third dose booster

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial  (D7220C00001) showed that AstraZeneca COVID-19 Vaccine, when given as a third dose  booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2  variants, while a separate analysis of samples from the trial showed increased antibody  response to the Omicron variant. 

The results were observed among individuals previously vaccinated with either AstraZeneca  COVID-19 Vaccine or an mRNA vaccine. 

A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a third  dose of AstraZeneca COVID-19 Vaccine substantially increased antibody levels following a  primary vaccine series with CoronaVac (Sinovac Biotech).1 

These data add to the growing body of evidence supporting AstraZeneca COVID-19 Vaccine as a third dose booster irrespective of the primary vaccination schedules tested.2,3 The  Company is submitting these additional data to health authorities around the world given the  urgent need for third dose boosters. 

Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said:  AstraZeneca COVID-19 Vaccine has protected hundreds of millions of people from COVID 19 around the world and these data show that it has an important role to play as a third dose  booster, including when used after other vaccines. Given the ongoing urgency of the pandemic and AstraZeneca COVID-19 Vaccine increased immune response to the Omicron variant, we  will continue to progress regulatory submissions around the world for its use as a third dose  booster.” 

Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at  the University of Oxford, said: “These important studies show that a third dose of AstraZeneca  COVID-19 Vaccine after two initial doses of the same vaccine, or after mRNA or inactivated  vaccines, strongly boosts immunity against COVID-19. The Oxford-AstraZeneca vaccine is  suitable as an option to enhance immunity in the population for countries considering booster  programmes, adding to the protection already demonstrated with the first two doses.”

AstraZeneca PLC 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom +44 (0)20 3749 5000 | astrazeneca.com 

The D7220C00001 safety and immunogenicity trial showed that AstraZeneca COVID-19  Vaccine continued to be generally well tolerated. Further analyses from the trial are expected  in the first half of 2022. 

Previous studies support AstraZeneca COVID-19 Vaccine as a third dose booster as part of  a homologous or heterologous schedule.2,3 In a sub-analysis from the COV001 and COV002  trials, a third dose of AstraZeneca COVID-19 Vaccine given at least six months after a second  dose significantly boosted antibody levels and maintained T cell response.2It also resulted in  higher neutralising activity against the Alpha, Beta, and Delta variants, compared with a two 

dose regimen.2 The COV-BOOST trial also showed that a third dose booster of AstraZeneca  COVID-19 induced significantly higher immune responses compared with controls against the  Delta variant and original strain following a primary vaccine series of AstraZeneca COVID-19  or Pfizer BioNtech (BNT162b2).3 

Notes 

D7220C00001 Trial 

D7220C00001 is an ongoing partially double-blind, randomised, multinational, active controlled trial in both previously vaccinated and unvaccinated adults to determine the safety  and immunogenicity of AstraZeneca COVID-19 Vaccine and AZD2816, a vaccine developed  for the prevention of COVID-19 caused by the Beta variant of the SARS-CoV-2 virus.4 

Immunogenicity data for the preliminary analysis were from samples taken 28 days after the  third dose booster vaccination. Individuals included in the preliminary analysis of the trial had  been fully vaccinated with two doses of AstraZeneca COVID-19 Vaccine (n=700), or an  mRNA-based vaccine (n=600), prior to being given a third dose booster vaccination of  AstraZeneca COVID-19 Vaccine or AZD2816 at least three months after their last injection. 

RHH-001 Phase IV Trial 

The Phase IV randomized, single-blind, two-centre trial assessed the safety and  immunogenicity of a third heterologous booster dose of either AstraZeneca COVID-19  Vaccine, an mRNA vaccine (BNT162b2, Pfizer/BioNTech), or a recombinant adenoviral  vectored vaccine (AD26.COV2-S, Janssen), compared with a third homologous booster dose  of CoronaVac in Brazilian adults who had received two doses of CoronaVac six months  previously. Between 16 August 2021 and 1 September 2021, 1,240 participants were  randomised to receive a third dose booster in São Paulo and Salvador, of whom 1,239 were  vaccinated.1 

The primary outcome of the trial was non-inferiority of anti-spike IgG antibodies 28 days after  the booster dose in the heterologous boost groups compared with homologous regimen.1 

AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant], formerly AZD1222) AstraZeneca COVID-19 Vaccine was invented by the University of Oxford. It uses a  replication-deficient chimpanzee viral vector based on a weakened version of a common cold  virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of  the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced,  priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more  than 90 countries. It also has Emergency Use Listing from the World Health Organization,  which accelerates the pathway to access in up to 144 countries through the COVAX Facility. 

Under a sub-license agreement with AstraZeneca, the vaccine is manufactured and supplied  by the Serum Institute of India under the name COVISHIELD.  

In the Philippines, the COVID-19 Vaccine (ChAdOx1-S [recombinant]) COVAX Supply has  been given ‘emergency use listing’ by the World Health Organization. Similarly, the direct  supply has been granted Emergency Use Authorization (EUA) by the Philippine Food and  Drug administration (FDA). This means that there is more evidence to come about this  medicine. The World Health Organization and the Philippine FDA will review new information  on this medicine as it becomes available, and the leaflet will be updated as necessary. Please  also note the vaccine cannot be marketed or sold, advertised, and promoted.